Stock TRUMY TERUMO CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Terumo Corporation OTC Markets

Equities

TRUMY

US88156J1051

Delayed OTC Markets
Other stock markets
 11:16:06 17/06/2024 pm IST 		5-day change 1st Jan Change
16.37 USD -0.41% Intraday chart for Terumo Corporation -5.69% +0.38%
11/06 Japan's Nikkei rises on US stocks, heavyweight chip shares RE
28/05 Terumo Cardiovascular Announces 510(K) Clearance for the CDI Oneview?? Monitoring System CI

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

Strengths

  • The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
  • The company is in a robust financial situation considering its net cash and margin position.
  • Over the last twelve months, the sales forecast has been frequently revised upwards.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • Over the past four months, analysts' average price target has been revised upwards significantly.
  • Over the past twelve months, analysts' opinions have been strongly revised upwards.
  • Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.

Weaknesses

  • With an expected P/E ratio at 35.5 and 30.19 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
  • With an enterprise value anticipated at 4.25 times the sales for the current fiscal year, the company turns out to be overvalued.
  • The company appears highly valued given the size of its balance sheet.
  • The valuation of the company is particularly high given the cash flows generated by its activity.
  • The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.

Ratings chart - Surperformance

Sector: Medical Equipment, Supplies & Distribution

1st Jan change Capi. Investor Rating ESG Refinitiv
TERUMO CORPORATION Stock Terumo Corporation
+0.38% 24.77B -
ABBOTT LABORATORIES Stock Abbott Laboratories
-6.09% 180B
C+
MEDTRONIC PLC Stock Medtronic plc
-3.16% 106B
C
BECTON, DICKINSON AND COMPANY Stock Becton, Dickinson and Company
-4.30% 67.55B
A
DEXCOM, INC. Stock DexCom, Inc.
-5.09% 46.11B
B-
CENCORA, INC. Stock Cencora, Inc.
+14.06% 45.79B
B-
HOYA CORPORATION Stock Hoya Corporation
+2.58% 41.61B
B+
METTLER-TOLEDO INTERNATIONAL, INC. Stock Mettler-Toledo International, Inc.
+19.19% 31.07B
B
WEST PHARMACEUTICAL SERVICES, INC. Stock West Pharmaceutical Services, Inc.
-3.99% 24.27B
A-
ZIMMER BIOMET HOLDINGS, INC. Stock Zimmer Biomet Holdings, Inc.
-12.15% 22.05B
B
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. 4543 Stock
  4. TRUMY Stock
  5. Ratings Terumo Corporation